USP17L2 and hepatocellular carcinoma: Our results showed that overexpression of DUB3 enhanced the sensitivity of HCC cells to doxorubicin hydrochloride and cisplatin, whereas knockdown of DUB3 reduced the sensitivity of HCC cells to 5-FU and cisplatin.